CD4 and tuberculosis: Future studies should include longitudinal monitoring of patients to provide more detail regarding treatment outcomes, such as the severity of both DR-TB and HIV disease, and the time-varying variables, such as viral load, CD4 count, adverse events, and changes in regimen composition.